The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://twitter.com/stillgray/status/1338208413235331073?s=21
Thats tells a story abt how long the experts think this will be under control - positive for sng
https://twitter.com/captainnasdaq/status/1328378859520200706?s=21
Synairgen soars after positive news from drug trial
Shares in biotech company Synairgen soared on Friday morning, after positive data from its trial of an immunosuppressant drug in Covid-19 patients was published in a leading medical journal.
Aim-traded Synairgen has been monitoring the effects of SNG001, an inhaled version of the drug interferon beta in hospitalised coronavirus patients. The drug is given to patients via a nebuliser.
Phase two or mid-stage trial data detailed in the Lancet Respiratory Medicine journal showed that SNG001 gave patients “greater odds of improvement” and they “recovered more rapidly” from Covid-19 infection. Trial participants, numbering 101 in total, were randomised. Some received the drug and some received a placebo.
Synairgen, which was spun out from Southampton university, said in July that it had observed positive top-line results from its initial SNG001 trial. Further details were wrapped into September’s half-year results.
The trial results “confirm our belief that interferon beta, a widely known drug approved for use in its injectable form for other indications, may have the potential as an inhaled drug to restore the lung's immune response and accelerate recovery from Covid-19”, said Tom Wilkinson, a professor at the University of Southampton and lead trial author.
The group’s share price climbed by more than a quarter on Friday to 130p, taking its market value to £258m.
The shares have rocketed this year, buoyed by updates on the SNG001 trial. They began the year at under 6p.
They were, however, badly hit earlier this week after news of a major vaccine breakthrough sparked concerns that the need for its virus treatment could wane.
https://www.ft.com/content/57426a84-a857-3a32-ba5e-106def4f8456
https://twitter.com/maryau_mcu_ph/status/1327144553044971521?s=21
And Mary Aurelien is back at it
Followed by synairgen ;) we could see something on twitter tonight...
https://twitter.com/lancetrespirmed?s=21
Today price action was as if a successful vaccine wasnt priced in... which is absurd! We all know we need both and we all have been expecting a vaccine to be made available by year end, latest q1 2021...
not sure if posted yet but came across this for November 18th:
https://www.sharesoc.org/events/sharesoc-webinar-with-synairgen-sng-18-november-2020/
This is December 20th. RNS comes in announcing very promising preliminary phase 3 trial results.
Vaccine candidates are accumulating delays and delivery/distribution logistics are expected to be more complex than initially planned. Treatment options are starting to gain more media attention as the long held promise of vaccine salvation is starting to fade.
SNG is trading at 320 and brokers are revising their estimates.
RM wishes us a merry christmas on a proactive interview.
Have a good weekend all and excuse my english.
Do you guys know if there is a deadline to submit TR1s once you are above the threshold? and what would trigger the need to declare? I understand that 15m shares are being admitted to trading today from the firm placing shares... and the remaining 31m which are the conditional ones will be admitted on november 4th... assuming the need to declare happens once they are admitted to trading on AIM, i guess we re unlikely to see any TR1 before november, unless the first 15M was absorbed 2-3 players, since 10M shares would give u 5% of the company? thoughts?